![George Elston](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
George Elston
Financieel Directeur/CFO bij EYEPOINT PHARMACEUTICALS, INC.
Vermogen: 508 511 $ op 31-05-2024
Profiel
George O.
Elston has founded Chatham Street Partners in 2010.
He is currently working as an Independent Trustee at db-X ETF Trust since 2010 and as the Chief Financial Officer & Executive Vice President at EyePoint Pharmaceuticals, Inc. since 2019.
Previously, he held positions such as President & Chief Executive Officer at Enzyvant, Inc. from 2018 to 2019, President & Chief Executive Officer at Oncology Venture US, Inc. from 2017 to 2018, and Director at AVANT Immunotherapeutics, Inc. in 2008.
He also served as an Independent Director at Celldex Therapeutics, Inc. from 2008 to 2017.
Additionally, he has held various other positions including Director at Celldex Therapeutics, Inc., Principal at C.
R.
Bard, Inc. (New Jersey), Chief Financial Officer, Secretary & Treasurer at Catalent JNP, Inc. from 2014 to 2016, Vice President-Finance at Elusys Therapeutics, Inc. from 2000 to 2009, Chief Financial Officer & Senior Vice President at KBI Biopharma, Inc. from 2013 to 2014, Chief Operating & Financial Officer at Optherion, Inc. from 2008 to 2010, and Chief Financial Officer at Enzyvant Therapeutics, Inc. from 2018 to 2019.
He also has a degree from Pace University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
25-05-2024 | 47 480 ( 0.09% ) | 508 511 $ | 31-05-2024 |
Actieve functies van George Elston
Bedrijven | Functie | Begin |
---|---|---|
EYEPOINT PHARMACEUTICALS, INC. | Financieel Directeur/CFO | 14-11-2019 |
db-X ETF Trust | Directeur/Bestuurslid | 01-10-2010 |
Eerdere bekende functies van George Elston
Bedrijven | Functie | Einde |
---|---|---|
Enzyvant Therapeutics, Inc.
![]() Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Enzyvant Therapeutics, Inc. develops biopharmaceutical products. It focuses on developing transformative therapies for rare diseases with high unmet needs. The company is headquartered in Cambridge, MA. | Financieel Directeur/CFO | 01-09-2019 |
Enzyvant, Inc.
![]() Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Algemeen Directeur | 01-09-2019 |
Oncology Venture US, Inc.
![]() Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Algemeen Directeur | 01-10-2018 |
CELLDEX THERAPEUTICS, INC. | Directeur/Bestuurslid | 15-06-2017 |
JUNIPER PHARMACEUTICALS INC | Financieel Directeur/CFO | 31-12-2016 |
Opleiding van George Elston
Pace University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
EYEPOINT PHARMACEUTICALS, INC. | Health Technology |
CELLDEX THERAPEUTICS, INC. | Health Services |
Bedrijven in privébezit | 15 |
---|---|
C. R. Bard, Inc. (New Jersey)
![]() C. R. Bard, Inc. (New Jersey) Medical SpecialtiesHealth Technology C. R. Bard, Inc. engages in designing, development, manufacturing, packaging, distribution, and sales of medical, surgical, diagnostic, and patient care devices. It sells its products to hospitals, individual healthcare professionals, extended care facilities, and alternate site facilities. The company was founded by Charles Russell Bard in 1907 and is headquartered in Franklin Lakes, NJ. | Health Technology |
Catalent JNP, Inc.
![]() Catalent JNP, Inc. Pharmaceuticals: MajorHealth Technology Catalent JNP, Inc. engages in the research and development of drugs and therapeutics. It offers analytical characterization and pre-formulation testing; formulation development; and clinical manufacturing of capsules and tablets. The company was founded in December 1986 and is headquartered in Somerset, NJ. | Health Technology |
AVANT Immunotherapeutics, Inc.
![]() AVANT Immunotherapeutics, Inc. Medical SpecialtiesHealth Technology AVANT Immunotherapeutics, Inc. is a biopharmaceutical company. Discovers, develops and commercializes vaccines and therapeutics that address various applications including cardiovascular, viral and bacterial diseases. The company markets Rotarix for rotavirus infection and Megan Egg and Megan Vac 1 for Salmonella infection in chicken. It's immunotherapeutic products include TP10 for cardiac bypass surgery and CETi for cholesterol management. The company develops various bacterial vaccines including CholeraGarde for cholera, Ty800 for typhoid fever and Injectable Anthrax for anthrax infection. AVANT Immunotherapeutics has various products in preclinical development stages which include ETEC for Enterotoxigenic E coli infection, Shigella for dysentery, campylobacter for campylobacter infection, Oral Anthrax and Plague vaccines and other food safety and animal health vaccines. AVANT Immunotherapeutics was organized in 1983 and is headquartered in Needham, MA. | Health Technology |
Celldex Therapeutics, Inc. (Old)
![]() Celldex Therapeutics, Inc. (Old) BiotechnologyHealth Technology Celldex Therapeutics, Inc. discovers, develops and commercialized novel immunotherapeutics. It offers treatment for cancer, infectious diseased and immune system disorders. The company was founded in May, 2003 and is headquartered in Philipsburg, NJ. | Health Technology |
Elusys Therapeutics, Inc.
![]() Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
KBI Biopharma, Inc.
![]() KBI Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services KBI Biopharma, Inc. provides drug development and contract manufacturing services. It helps client partners accelerate and optimize drug development and manufacturing programs by offering an extensive suite of expert development and manufacturing services. The firm offers services to global pharmaceutical and biotechnology companies, and academic and non-profit organizations. The company was founded in 1996 and is headquartered in Durham, NC. | Commercial Services |
Optherion, Inc.
![]() Optherion, Inc. Medical SpecialtiesHealth Technology Optherion, Inc. develops therapeutic products. It develops products to diagnose and treat dry and wet Age-related Macular Degeneration and other chronic diseases involving the alternative complement system. The company was founded by Gregory S. Hageman, David I. Scheer and Sandy Gordon in 2005 and is headquartered in New Haven, CT. | Health Technology |
db-X ETF Trust | Miscellaneous |
Trillium USA, Inc. | Utilities |
Celldex Research Corp.
![]() Celldex Research Corp. Miscellaneous Commercial ServicesCommercial Services Celldex Research Corp. engages in provision of biological research and development. The company is headquartered in Phillipsburg, NJ. | Commercial Services |
Pricewaterhousecoopers LLC | |
Chatham Street Partners | |
Oncology Venture US, Inc.
![]() Oncology Venture US, Inc. Miscellaneous Commercial ServicesCommercial Services Oncology Venture US, Inc. develops therapies for cancer treatment. The company is headquartered in Cambridge, MA. | Commercial Services |
Enzyvant, Inc.
![]() Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Enzyvant, Inc. develops biopharmaceutical products. The company is based in Cambridge, MA. William T. Symonds has been the CEO of the company since 2022. | Health Technology |
Enzyvant Therapeutics, Inc.
![]() Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Enzyvant Therapeutics, Inc. develops biopharmaceutical products. It focuses on developing transformative therapies for rare diseases with high unmet needs. The company is headquartered in Cambridge, MA. | Health Technology |